Summary
• Relay Therapeutics reported a 3.69% pre-market increase in stock price to $6.75 following strong Q3 2025 results, which included positive developments in clinical trials and board appointments.
• The company ended the quarter with approximately $596 million in cash, reporting an EPS of -$0.43, exceeding expectations of -$0.39.
• Analysts maintain a “Buy” rating for Relay Therapeutics, with Wells Fargo increasing its price target from $4 to $6 based on the company’s recent progress and robust cash position.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is seeing a notable uptick in pre-market trading, rising to $6.75, up 3.69% from its last closing price of $6.51. The movement comes on the heels of its recent financial results announcement, where the company reported significant updates related to its clinical trials and board appointments.
Earnings Spark Sharp Move
On November 6, 2025, Relay Therapeutics reported its third-quarter 2025 financial results, revealing a continued focus on the execution of RLY-2608 clinical trials aimed at PI3Kα-mutated breast cancer and vascular malformations. Notably, the company ended the quarter with approximately $596 million in cash and cash equivalents, bolstering its financial positioning amid ongoing developments. The earnings report indicated an actual EPS of -$0.43, which was higher than the estimated -$0.39, showcasing a positive surprise of over 10%.
In conjunction with this, Relay announced two appointments to its Board of Directors: Lonnel Coats and Habib Dable, both of whom bring significant biotechnology leadership experience to the company.
Market and Technical Picture
As of the latest session, RLAY’s weekly performance has shown a decline of 15.3%, though it has rebounded significantly over the quarter, achieving a robust 86.2% increase. With a relative strength index (RSI) of 52.17, the stock is positioned in neutral territory, which suggests some potential for momentum in either direction. The stock trades with an average volume of approximately 2.3 million over the last 10 days, well above its 3-month average of 1.8 million, indicating increased investor interest following its latest developments.
Analyst Sentiment
Currently, Relay Therapeutics holds a “Buy” rating from analysts, suggesting positive sentiment regarding its future performance. Recently, Wells Fargo maintained its rating of “Equal-Weight” for the stock but adjusted the price target from $4 to $6, reflecting optimism based on the company’s recent progress and cash position.
With shares reacting strongly to the latest results and updates, investors appear encouraged by Relay’s advancements in clinical trials and its solid financial foundation as it continues to navigate the competitive biotech landscape.